EPCAM and cancer: Hwajung et al. [33] showed that the percentage of CD133+EpCAM+ cancer stem cell (CSC) populations was significantly increased in hepatocellular carcinoma cell lines Huh7 and HEP3B, when treated with mTOR inhibitors, sirolimus and everolimus.